Reuters Gets Shredded for Anon 'Person Familiar With the Matter' Spin on Tulsi...
Power Hungry: Wasserman Schultz Invades Majority-Black District After Redistricting Wipes...
Rep. Thanedar Slammed as Disgusting and Vile for Attacking Tulsi Gabbard While Her...
DNC's Photo Tribute to Colbert Speaks Volumes About What the Show Was REALLY...
Trump Announces Decision on Attending Don Jr.'s Wedding Amid Iran Tensions and X...
Democrats Stage Mutiny Against Schumer As Party Loses All Hope
Tulsi Gabbard Resigning as Director of National Intelligence, Trump Responds With Support
Dem Rep. Katherine Clark Tried Pushing Biden-Era BS on CNBC and Got Called...
NYT’s Disgusting Double Down: ‘Yes, Dogs Raped Palestinians’ — And It’s Your Fault...
Navy SEAL Who Took Out Osama Bin Laden Rails Against Graham Platner for...
Brian Stelter Noticed Whose Name Was Not Mentioned During Colbert's Final Show (Too...
Deflection Level: Expert. Newsom Blames Chevron for Prices His Policies Created
Justine Bateman RIPS Gov. Newsom's 'Press Office' a New You-Know-What Over Call to...
Colbert Devotees Will Be Giddy About His Final Vengeful Attempt to Cost CBS...
The White House Does the Meme -- In a GOOD Way -- As...

Christina Pushaw busts the AP for acknowledging a COVID treatment fact they shamed Ron DeSantis for pointing out just a few months ago

Yesterday, the Associated Press’ Matthew Perrone reported a possible setback for a couple of COVID19 treatments, including Regeneron.

Advertisement

More from the AP:

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.

The fact that Regeneron may not be as effective against the omicron variant as it’s been against others is noteworthy enough. But Gov. Ron DeSantis’ press secretary Christina Pushaw finds something else noteworthy, too:

Things sure have changed, haven’t they? Recall this past August, when the AP was entertaining the idea that DeSantis was promoting sketchy Regeneron in some kind of quid pro quo scheme because one of his top donors had invested money in Regeneron, making DeSantis shady AF and not to be trusted.

Advertisement

Pushaw called out the AP then.

Just like she’s calling out the AP now.

We’ve got whiplash.

And Pushaw’s got one last question for the AP:

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos